The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.
Adults age 18 years and older.
Ability to provide informed consent.
Willingness and ability to comply with study procedures and remote monitoring requirements.
Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation.
Individuals unable or unwilling to provide informed consent.
Individuals unable to comply with remote monitoring procedures or wearable device usage requirements.
Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity.
Current incarceration or institutionalization limiting voluntary participation.